Victor Stone
and Head of Cell Therapies at Alloy Therapeutics
Victor Stone
and Head of Cell Therapies at Alloy Therapeutics
Cambridge, Massachusetts
Overview
Work Experience
President of 82VS Venture Studios and Head of Cell Therapies
2023 - Current
Alloy democratizes access to pre-competitive drug discovery technologies and services across six biologic modalities, and I am very excited to be taking a foundational role in building out the discovery services organization for cell therapy. The company already has an incredible footprint in antibodies and TCRs that I'm thrilled to expand on to empower the drug discovery community in their cell therapy endeavors. Company creation is also an exciting part of Alloy's business through 82VS, and I'm excited to partner with the team there around new companies to advance cell-therapy-based assets. We are still early in these efforts but please reach out if you are interested in exploring ways to collaborate and #makemedicinetogether.
President of 82VS Venture Studios and General Partner of 82VS Fund
2023
Consortia Director
2020
Japan VC Consortia is a consortia of over 20 Japanese biopharma (Pharma BD/CVC and Institutional VC) hosted by Shonan Health Innovation Park dedicated to actionable initiatives to advance the Japanese biotech ecosystem
Co-Founder
2021
Non Executive Director
2019
Largest small molecule platform in Japan, now a full-service pre-clinical CRO serving Japanese Biopharma clients. Spin out of R&D capabilities of Takeda Shonan Research Center including 240 high performing researchers
Senior Investment Director and Partner
2020 - 2023
Investments with focus in cell and gene therapies and new chemical space. Board Directorships summarized below. Board Observer roles include: Artisan Development Labs (Cas12a), Be BioPharma (Engineered B-Cell), Bridgene (PPI SMOL), RedPin Tx (AAV CNS), X-forest Tx (RNAi). Promoted to role in October 2021.
Non Executive Director
2021 - 2023
Non-viral gene delivery platform based on 3-DNA scaffold technology. Versatile platform enabling base construct of 18 points for engagers and gene cargo. Unprecedented signal-noise ratio with tissue specific targeting.
Non Executive Director
2022 - 2023
Synthetic Promoter developer enabling tissue specific expression in gene therapy and optimization of biologics manufacturing. Spinout from University of Sheffield, David C James and Adam Brown labs
Member Of The Supervisory Board
2021 - 2023
Mobile Diagnostics enabling point of care measurement of hematology biomarkers including Factor VIII, Von Willebrand Factor and Thrombin
Non Executive Director
2021 - 2022
Spinout from GammaDelta Therapeutics and supported by Abingworth and Takeda. Antibody approach to harness innate immune potential of gdT-cells for cancer immuno-therapy. Acquired by Takeda in April 2022